Compare General Motors Company (GM) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Moderna, Inc. — how do they compare? General Motors Company trades at $76.79 (market cap $70.01B), while Moderna, Inc. trades at $63.73 (market cap $27.09B). The key difference: General Motors Company is far larger — about 2.6× Moderna, Inc.'s market cap, and General Motors Company pays a 0.93% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| GM | MRNA | |
|---|---|---|
Market Cap | $70.01B | $27.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $86.38 | $81.80 |
52-Week Low | $48.89 | $22.36 |
Enterprise Value | $173.34B | $23.19B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $76.78, down 0.12% on the day, with a neutral technical signal and strong analyst support (63% buy ratings). Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $3.70 surpassing the $2.61 estimate. Revenue for 2025 was $185.02B, though net income margin narrowed to 1.38%. The company maintains solid cash flow from operations of $26.87B in 2025 and recently announced a $0.18 dividend for H1 2026.
GM presents a value opportunity with low P/S (0.4) and P/B (1.12) ratios, trading below the consensus price target of $102.00. Upside potential is supported by earnings beats and strategic investments in energy and autonomous driving, but risks include margin pressure, rising debt levels (46.79% debt-to-asset in 2024), and competitive auto market dynamics. Institutional sentiment remains bullish despite near-term headwinds.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
